Use of Alternative Medicine in Patients With Dementia and Mild Cognitive Dysfunction
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Use of Alternative Medicine Among Patients With Dementia and Mild Cognitive Dysfunction|
- Number of patients taking alternative medicines [ Time Frame: Up to 2 years ]The patient's use of alternative medicine(s) on a given point of time (the consultation date) as reported by the patient or by the next of kin who is the patient's companion during the consultation. The results will be presented as the number of patients taking alternative medicines
- Numbers of potential and clinical relevant interactions [ Time Frame: Up to 2 years ]Assessment of the potential of interactions between the patient's alternative medicines and prescribed or over-the-counter drugs in use at the date of the consultation. The assessment will be based on data from litterature reports. Results will be presented as numbers of potential and clinical relevant interactions.
- The patient's subjective experiences with alternative medicines [ Time Frame: up to 2 years ]In the interview the patients will be asked to tell if they have experienced positive, negative, or no effects related to their use of alternative medicines. Results will be presented as number of patients.
|Study Start Date:||March 2012|
|Study Completion Date:||October 2014|
|Primary Completion Date:||October 2014 (Final data collection date for primary outcome measure)|
Patients: All patients with a diagnosis of dementia under follow-up at the out-patient clinic are invited to participate, if giving a written consent.
Method: a semi-structured interview is undertaken by the doctor at the end of the consultation. Patients and their company are asked to name their alternative medicines (if any), for how long the products have been used, where and how they learned about the products, ant to tell about their experiences with the products (i.e if they have noticed effects or side-effects). After the consultation information of the the actual product's contents and properties are obtained and an assessment of possible interactions with the patient's other drugs (prescriptions and self-reported use of over-the-counter drugs) is made. Reported effects or side-effects are registered.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01554475
|Bodø, Norway, N-8076|
|Study Chair:||Trude Giverhaug, PhD||University Hospital North-Norway|